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Objective: To evaluate the 24-month efﬁcacy and safety of intravitreal ranibizumab 0.5 mg and 2.0 mg
administered monthly or as needed (pro re nata [PRN]) in patients with neovascular age-related macular
degeneration (wet AMD).
Design: Twenty-four-month, multicenter, randomized, double-masked, active treatment-controlled phase 3
trial.
Participants: Patients (n ¼ 1098) 50 years of age with treatment-naïve subfoveal wet AMD.
Methods: Patients were randomized to receive intravitreal injections of ranibizumab 0.5 mg or 2.0 mg
monthly or PRN after 3 monthly loading doses.
Main Outcome Measures: The primary efﬁcacy end point was the mean change in best-corrected visual
acuity (BCVA) from baseline at month 12. Key secondary end points included mean change in BCVA from
baseline at month 24, proportion of patients who gained 15 letters in BCVA, mean number of ranibizumab
injections, and mean change in central foveal thickness from baseline over time by spectral-domain optical
coherence tomography. Ocular and systemic safety events also were evaluated through month 24.
Results: At month 24, the mean change from baseline in BCVA was (letters) þ9.1 (0.5 mg monthly), þ7.9
(0.5 mg PRN), þ8.0 (2.0 mg monthly), and þ7.6 (2.0 mg PRN). The change in mean BCVA from month 12 to 24
was (letters) 1.0, 0.3, 1.2, and 1.0, respectively. The proportion of patients who gained 15 letters from
baseline in BCVA at month 24 was 34.5%, 33.1%, 37.6%, and 34.8%, respectively. The mean number of rani-
bizumab injections through month 24 was 21.4, 13.3, 21.6, and 11.2, respectively; 5.6 and 4.3 mean injections
were required in year 2 in the 0.5 mg and 2.0 mg PRN groups, respectively. The average treatment interval in the
0.5 mg PRN group was 9.9 weeks after 3 monthly loading doses, and 93% of these patients did not require
monthly dosing. Ocular and systemic safety proﬁles over 2 years were similar among all 4 treatment groups and
were consistent with previous ranibizumab trials in AMD.
Conclusions: At month 24, mean BCVA improvements were clinically meaningful and similar among all 4
ranibizumab treatment groups. The 0.5 mg PRN group achieved a mean gain of 7.9 letters at month 24 with an
average of 13.3 injections (5.6 injections in year 2). No new safety events were identiﬁed over 24
months. Ophthalmology 2014;121:2181-2192 ª 2014 by the American Academy of Ophthalmology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
*Supplemental material is available at www.aaojournal.org.Strategies to improve treatment effectiveness for neovascular
age-related macular degeneration (wet AMD) aim to enhance
visual function and reduce treatment burden, characterized by
frequent intravitreal injections and patient encounters.
Improved strategies are impactful because wet AMD affects
approximately 1.75 million individuals in the United States
and remains a leading cause of blindness among adults older
than 50 years of age inmany regions of the world.1,2 Although
the underlying disease pathogenesis has not been elucidated
fully, vascular endothelial growth factor (VEGF) has been 2014 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/). Published by Elsevier Inc.shown to play a key role in the development of choroidal
neovascularization (CNV), which can lead to severe vision
loss if left untreated.2,3 Anti-VEGF agents have become the
standard-of-care treatment option for the management of wet
AMD.4e12 Evidence from prospective, randomized clinical
trials of intravitreal anti-VEGF therapy for the treatment of
wet AMD demonstrate that visual outcomes are, on average,
signiﬁcantly improved from baseline after treatment, and the
rates of serious ocular and systemic adverse events (AEs) are
low and generally well tolerated.4e132181http://dx.doi.org/10.1016/j.ophtha.2014.05.009
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ment of Predominantly Classic Choroidal Neovascularization
in Age-Related Macular Degeneration (ANCHOR)4,5 and
Minimally Classic/Occult Trial of the Anti-VEGF Antibody
Ranibizumab in the treatment of Neovascular AMD
(MARINA),6 were the ﬁrst phase 3 clinical trials to
demonstrate that administration of 0.3 mg and 0.5 mg
ranibizumab (Lucentis; Genentech, Inc., South San
Francisco, CA)da humanized, monoclonal anti-VEGF anti-
gen binding fragment speciﬁcally designed for intraocular use
that neutralizes all active isoforms of VEGF-A14dnot only
prevented vision loss associated with wet AMD, but also
improved mean visual acuity (VA) over 2 years. Most of
the functional and anatomic outcomes favored the 0.5 mg
dose; in ANCHOR, the mean change from baseline in best-
corrected VA (BCVA) at month 24 was þ10.7 letters for
ranibizumab 0.5 mg (n¼ 139) compared withþ8.1 letters for
ranibizumab 0.3 mg (n¼ 140) and9.8 letters for verteporﬁn
photodynamic therapy (n ¼ 143). In MARINA, the mean
change from baseline in BCVA at month 24 was þ6.6 letters
for ranibizumab 0.5 mg (n¼ 240) compared withþ5.4 letters
for ranibizumab 0.3 mg (n¼ 238) and14.9 letters for sham
injection (n ¼ 238). An open-label, dose-ranging study
demonstrated that ranibizumab doses up to 2.0 mg are well
tolerated,15 and the 2.0 mg dose has been shown to improve
visual and anatomic outcomes signiﬁcantly in wet AMD pa-
tients who were recalcitrant to ranibizumab 0.5 mg therapy.16
Although patients in the ANCHOR and MARINA trials
received monthly ranibizumab injections, many retina spe-
cialists in clinical practice individualize treatment regimens
in an effort to reduce patient burden.17 Variable dosing
regimens, such as treat-and-extend and pro re nata (PRN;
as needed) administration, are used frequently and may
reduce treatment burden.17,18 Nonmonthly treatment ap-
proaches with VEGF inhibitors have been investigated in
several clinical trials.7e12,19e21 Visual outcomes were most
favorable when optical coherence tomography (OCT) was
useddin addition to VA decline criteriadto initiate PRN
treatment for recurrent macular ﬂuid.22,23 For example, in
the 2-year Prospective Optical Coherence Tomography
Imaging of Patients with Neovascular AMD Treated with
Intra-Ocular Lucentis (PRONTO) study, 40 patients
received 3 monthly loading doses of ranibizumab 0.5 mg
and were monitored monthly and re-treated based on time-
domain OCT and VA criteria.22,23 At month 24, patients
treated with ranibizumab 0.5 mg PRN achieved comparable
VA gains (þ11.1 letters), as did the ﬁxed monthly ranibi-
zumab 0.5 mg dosing arms in ANCHOR (þ10.7 letters) and
MARINA (þ6.6 letters), but with fewer injections over 2
years (on average, 9.9 injections in the PRONTO study
versus the 24 scheduled injections in both ANCHOR and
MARINA).22,23 Pro re nata therapy was adopted by many
retina specialists after the results of the PRONTO study. In
the past few years, OCT technology has advanced, with
practices now routinely using higher-resolution spectral-
domain OCT (SD-OCT), which is more sensitive than time-
domain OCT for the detection of ﬂuid.24
The pHase III, double-masked, multicenter, randomized,
Active treatment-controlled study of the efﬁcacy and safety
of 0.5 mg and 2.0 mg Ranibizumab administered monthly or2182on an as-needed Basis (PRN) in patients with subfoveal
neOvasculaR age-related macular degeneration (HARBOR)
evaluated over 2 years the potential beneﬁcial effects of both
a higher dose and PRN dosing of ranibizumab after 3
monthly loading doses compared with 0.5 mg ranibizumab
monthly on functional and anatomic outcomes in patients
with treatment-naïve subfoveal wet AMD.7 At 12 months
(the primary end point), the ranibizumab 2.0 mg monthly
dose was not superior to the 0.5 mg monthly dose and did
not offer any incremental improvements in efﬁcacy out-
comes (model-adjusted mean difference, 1.1 letters;
95.1% conﬁdence interval, 3.4 to 1.3; P ¼ 0.8145).7
Additionally, the ranibizumab 0.5 mg PRN and 2.0 mg
PRN groups failed to meet the prespeciﬁed 4-letter non-
inferiority margin compared with the 0.5 mg monthly group
(noninferiority comparison between 0.5 mg PRN and
0.5 mg monthly: model-adjusted mean difference, 2.0
letters [97.5% conﬁdence interval, 4.5 to 0.6]; non-
inferiority comparison between 2.0 mg PRN and 0.5 mg
monthly: model-adjusted mean difference, 1.6 letters
[98.4% conﬁdence interval, 4.4 to 1.1]).7
Despite not meeting prespeciﬁed superiority and non-
inferiority comparisons, the HARBOR year 1 results
demonstrated that PRN dosing with ranibizumab using VA
and SD-OCTeguided re-treatment criteria decreased treat-
ment burden and provided similar VA gains as monthly
dosing for the treatment of wet AMD. The mean change in
BCVA from baseline at month 12 was þ8.2 and þ8.6 letters
in the ranibizumab 0.5 mg and 2.0 mg PRN groups,
respectively, compared with þ10.1 and þ9.2 letters in
ranibizumab 0.5 mg and 2.0 mg monthly groups, respec-
tively. Over the ﬁrst year, the ranibizumab 0.5 mg and
2.0 mg PRN groups required approximately 4 fewer in-
jections, on average, than the 0.5 mg and 2.0 mg monthly
groups (7.7 and 6.9 injections vs. 11.3 and 11.2 injections,
respectively).7 No new safety events were identiﬁed in year
1 of the HARBOR study. In particular, there was no
difference in the safety proﬁle regardless of dose group
(0.5 vs. 2.0 mg) or treatment regimen (monthly vs. PRN).7
The HARBOR study has been completed, and the 2-year
efﬁcacy and safety results are reported herein.Methods
The methods for the HARBOR study have been published previ-
ously7 and are summarized below.
Study Design and Eligibility
The HARBOR study was a 24-month, phase 3, randomized,
multicenter, double-masked, active treatment-controlled study
(ClinicalTrials.gov identiﬁer NCT00891735) with 100 investigator
sites across the United States. The HARBOR study was conducted
in accordance with Good Clinical Practice (International Confer-
ence on Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use E6), applicable United States
Food and Drug Administration regulations, and the Health Insur-
ance Portability and Accountability Act. Institutional review
boards approved the study protocol before the start of the study,
and all participants provided written informed consent for study
participation.
Figure 1. HARBOR treatment schedule. *Starting at month 3, pro re nata (PRN; as needed) groups were evaluated for re-treatment monthly and treated if
there was a 5-letter decrease from the previous visit or any evidence of disease activity on spectral-domain optical coherence tomography. All groups
continued on the same treatment schedule through month 24.
Ho et al  HARBOR Study 2-Year ResultsPatients were eligible to participate in the HARBOR trial if they
were 50 years of age and met the following key inclusion criteria
for the study eye: (1) BCVA of 20/40 to 20/320 (Snellen equiva-
lent), using Early Treatment Diabetic Retinopathy Study (ETDRS)
charts at a distance of 4 m; (2) active subfoveal lesions with classic
CNV, with some classic CNV component, or with purely occult
CNV; (3) total area of lesion <12 disc areas (DAs) or 30.48 mm2;
and (4) total CNV area constituting 50% or more of total lesion
area based on ﬂuorescein angiography. For the inclusion of purely
occult or occult with some classic CNV component, activity of the
lesion had to be demonstrated by one of several criteria, including a
10% increase in CNV lesion size at interval visits, a documented
visual loss of >1 line of Snellen vision, or the presence of hem-
orrhage at presentation. Key exclusion criteria for the study eye
were a history of vitrectomy surgery; prior treatment with photo-
dynamic therapy with verteporﬁn, external beam radiation therapy,
or transpupillary thermotherapy; previous intravitreal drug de-
livery; previous subfoveal laser photocoagulation; uncontrolled
blood pressure; atrial ﬁbrillation not managed by the patient’s
primary care physician or cardiologist within 3 months of the
screening visit; or a history of stroke within 3 months of the
screening visit.
Randomization and Treatment Schedule
One eye was chosen as the study eye for each patient. Eligible
patients received a computer-generated subject number on day
0 that randomly assigned patients in a 1:1:1:1 ratio to 1 of 4
ranibizumab treatment groups: 0.5 mg monthly, 0.5 mg PRN,
2.0 mg monthly, or 2.0 mg PRN. Randomization was stratiﬁed by
VA at day 0 (54 letters [approximate Snellen equivalent, 20/80 or
worse] vs. 55 letters [approximate Snellen equivalent, 20/80 or
better]); CNV classiﬁcation at baseline (predominantly classic,
minimally classic, or purely occult); and study center. All study site
personnel, the designated physician(s), central reading center
personnel, patients, and the sponsor and its agents were masked
to treatment drug dose assignment (0.5 vs. 2.0 mg) until study
completion. However, the sponsor and study personnel were
unmasked to the treatment assignment after analysis of the year 1
data. Fundus photographs and ﬂuorescein angiograms were ob-
tained at baseline and at months 3, 6, 12, 18, and 24; images were
not graded at month 18. Spectral-domain OCT was performed at
each study visit and images were graded at baseline, day 7, and
months 1 through 4, 6, 9, 12, 18, and 24. Fluorescein angiography
and SD-OCT images were read manually by a single central
reading center to provide an objective, masked assessment of these
evaluations.All patients were scheduled to receive 3 consecutive monthly
loading doses of intravitreal ranibizumab 0.5 mg or 2.0 mg at the
beginning of the study (day 0). The monthly groups then continued
with monthly dosing, whereas the PRN groups were evaluated
monthly and re-treated if there was a 5-letter decrease in vision
from the previous visit or any evidence of disease activity on
SD-OCT (e.g., intraretinal ﬂuid, subretinal ﬂuid, or subretinal
pigment epithelial ﬂuid) using Cirrus HD-OCT (Carl Zeiss Medi-
tec, Inc., Dublin, CA). There was no crossover between the treat-
ment groups over the course of the 2-year study (Fig 1).
Outcome Measures
The primary end point was the mean change in BCVA from
baseline at month 12 (previously reported).7 Key secondary end
points in year 2 included the mean change in BCVA from
baseline at month 24, the proportion of patients who gained 15
letters in BCVA, the mean number of ranibizumab injections,
and the mean change in central foveal thickness (CFT) from
baseline over time. Additional VA end points evaluated included
the proportion of patients with a Snellen equivalent of 20/40 or
better, the proportion of patients with a Snellen equivalent of
20/200 or worse, and the proportion of patients who lost <15
letters in BCVA from baseline.
Safety assessments included ocular and systemic safety events
through month 24. Assessments of targeted events included study
eye serious AEs (SAEs), Antiplatelet Trialists’ Collaboration
(APTC) arterial thromboembolic events (ATEs), and SAEs poten-
tially related to systemic VEGF inhibition.
Statistical Analysis
Analyses of efﬁcacy end points were based on the intent-to-treat
population, with patients grouped according to their treatment
assignment at randomization and missing data imputed using the
last observation carried forward method, unless otherwise noted.
Efﬁcacy analyses were stratiﬁed by baseline BCVA score (54 vs.
55 letters) and baseline CNV classiﬁcation (predominantly
classic, minimally classic, purely occult). The sample size of 1100
randomized patients ensured 80% power in the intent-to-treat
population analysis for the 3 primary comparisons at month 12
(a superiority comparison between 2.0 mg monthly and 0.5 mg
monthly and 2 noninferiority comparisons). The study was not
powered to compare efﬁcacy outcomes between the treatment
groups at month 24. Thus, efﬁcacy analyses over 2 years were
based on descriptive statistics, and presented statistical compari-
sons of efﬁcacy outcomes were performed post hoc. The incidence2183
Table 1. Patient Disposition during the 24-Month Treatment Period
Status
Ranibizumab Treatment Group, n (%)
0.5 mg Monthly
(N ¼ 275)
0.5 mg PRN
(N ¼ 275)
2.0 mg Monthly
(N ¼ 274)
2.0 mg PRN
(N ¼ 273)
Received study drug in study eye 274 (99.6) 275 (100.0) 274 (100.0) 272 (99.6)
In study at month 12 257 (93.5) 263 (95.6) 258 (94.2) 258 (94.5)
Completed study 230 (83.6) 237 (86.2) 239 (87.2) 237 (86.8)
Discontinued study 45 (16.4) 38 (13.8) 35 (12.8) 36 (13.2)
First year 17 (6.2) 12 (4.4) 16 (5.8) 15 (5.5)
Second year 28 (10.2) 26 (9.5) 19 (6.9) 21 (7.7)
Primary reason for study discontinuation in the second year
Adverse event 2 (0.7) 2 (0.7) 1 (0.4) 4 (1.5)
Death 5 (1.8) 6 (2.2) 5 (1.8) 4 (1.5)
Lost to follow-up 8 (2.9) 4 (1.5) 4 (1.5) 4 (1.5)
Physician’s decision to withdraw patient from study 0 (0) 1 (0.4) 1 (0.4) 2 (0.7)
Patient’s decision to withdraw from study 12 (4.4) 12 (4.4) 7 (2.6) 7 (2.6)
Sponsor’s decision to terminate study 1 (0.4) 0 (0) 0 (0) 0 (0)
Patient noncompliance 0 (0) 1 (0.4) 1 (0.4) 0 (0)
Discontinued treatment in study eye 47 (17.1) 37 (13.5) 39 (14.2) 36 (13.2)
First year 21 (7.6) 16 (5.8) 18 (6.6) 18 (6.6)
Second year 26 (9.5) 21 (7.6) 21 (7.7) 18 (6.6)
Primary reason for treatment discontinuation in the second year
Adverse event 3 (1.1) 2 (0.7) 3 (1.1) 3 (1.1)
Death 5 (1.8) 6 (2.2) 5 (1.8) 5 (1.8)
Lost to follow-up 7 (2.5) 4 (1.5) 2 (0.7) 3 (1.1)
Physician’s decision to discontinue treatment 0 (0) 1 (0.4) 2 (0.7) 2 (0.7)
Patient’s decision to discontinue treatment 10 (3.6) 7 (2.5) 7 (2.6) 5 (1.8)
Sponsor’s decision to terminate study 1 (0.4) 0 (0) 0 (0) 0 (0)
Patient noncompliance 0 (0) 1 (0.4) 2 (0.7) 0 (0)
PRN ¼ pro re nata (as needed).
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potentially related to systemic VEGF inhibition were summarized
for the cumulative 24-month study period with patients grouped
according to the actual treatment received during the ﬁrst year.
Results
Patient Disposition and Baseline Characteristics
Between July 2009 and August 2010, 1098 patients were enrolled
at 100 study centers across the United States and were randomized
in a 1:1:1:1 ratio to 1 of 4 ranibizumab treatment groups: 0.5 mg
monthly (n ¼ 276), 0.5 mg PRN (n ¼ 275), 2.0 mg monthly (n ¼
274), and 2.0 mg PRN (n ¼ 273). One patient in the 0.5 mg
monthly group was randomized before screening failure (no
baseline or postbaseline data were reported), and therefore 1097
patients were eligible for the study. In total, 86.0% of patients
completed the HARBOR study through month 24. Discontinuation
rates were similar between the 4 treatment groups; on average,
14.5% of patients discontinued from the study during the 24-month
treatment period; the most common reason was the patient’s de-
cision to withdraw (Table 1).
Patient demographics and baseline ocular characteristics for the
study eye were reported previously7 and were well-balanced
among the 4 treatment groups. Patients predominantly were
female (59%) and white (97%), and the mean age of all patients
was 79 years. At baseline, mean VA was between 53.5 and 54.5
letters (approximate Snellen equivalent, 20/80) and mean CFT
ranged from 333 to 348 mm among the 4 ranibizumab treatment2184groups. Overall, approximately 46% of patients had minimally
classic CNV lesions, 16% had predominantly classic lesions, and
38% had purely occult CNV. Total CNV area and total lesion area
ranged between 3.0 and 3.3 DAs and between 3.2 and 3.5 DAs,
respectively.7
Visual Acuity End Points
As previously reported by Busbee et al,7 the HARBOR study did
not meet its 3 primary end point comparisons at year 1.
However, all 4 ranibizumab treatment groups demonstrated
clinically meaningful and similar improvements in BCVA from
baseline, which were observed starting at day 7, continued
through month 12, and were sustained through month 24. The
mean changes in BCVA from baseline to month 24 were þ9.1
letters (0.5 mg monthly), þ7.9 letters (0.5 mg PRN), þ8.0 letters
(2.0 mg monthly), and þ7.6 letters (2.0 mg PRN) (Fig 2,
Table 2). From months 12 to 24, BCVA in the 0.5 mg PRN
group remained relatively unchanged (difference of 0.3 letters),
whereas the 0.5 mg monthly, 2.0 mg monthly, and 2.0 mg PRN
groups lost approximately 1 letter on average (1.0, 1.2,
and 1.0, respectively; Fig 2).
The proportion of patients who gained 15 letters in BCVA
from baseline (i.e., 3-line gainers using the ETDRS chart) at month
24 was 34.5%, 33.1%, 37.6%, and 34.5% in the 0.5 mg monthly,
0.5 mg PRN, 2.0 mg monthly, and 2.0 mg PRN groups, respec-
tively (Table 2). These percentages were similar to or slightly
higher than the percentage of those who gained 3 lines at month
12 (34.5%, 30.2%, 36.1%, and 33.0% for each ranibizumab
Figure 2. Graph showing the mean change in best-corrected visual acuity
(BCVA) from baseline up to month 24. The last observation carried for-
ward method was used to impute missing data. Vertical bars are 1 stan-
dard error of the mean. M ¼ month; PRN ¼ pro re nata (as needed).
Ho et al  HARBOR Study 2-Year Resultstreatment group, respectively). The proportion of patients who lost
<15 letters from baseline was explored post hoc and ranged from
93% to 98% at month 12 and 90% to 94% at month 24. The
proportion of patients with a Snellen equivalent of 20/40 or better
was similar between month 12 (range, 44%e52%) and month 24
(range, 45%e50%). The proportion of patients with a Snellen
equivalent of 20/200 or worse was numerically slightly higher at
month 24 (range, 10%e14%) compared with month 12 (range,
7%e12%; Table 2).Table 2. Key Visual Acuity End
0.5 mg Monthly
(N ¼ 275)
0.5 mg
(N ¼
Mean change in BCVA from
baseline, ETDRS letters (SD)
At month 12 10.1 (13.3) 8.2 (1
At month 24 9.1 (14.9) 7.9 (1
Proportion of patients gaining
15 letters from baseline
At month 12 95 (34.5) 83 (3
At month 24 95 (34.5) 91 (3
Proportion of patients losing
<15 letters from baseline
At month 12 269 (97.8) 260 (9
At month 24 259 (94.2) 250 (9
Proportion of patients with
Snellen 20/40 or better
Baseline 46 (16.7) 35 (1
At month 12 144 (52.4) 127 (4
At month 24 136 (49.5) 131 (4
Proportion of patients with
Snellen 20/200 or worse
Baseline 40 (14.5) 31 (1
At month 12 20 (7.3) 23 (8
At month 24 28 (10.2) 28 (1
BCVA ¼ best corrected visual acuity; ETDRS ¼ Early Treatment Diabetic Ret
Data are n (%) unless otherwise indicated.Treatment Frequency
The mean number of ranibizumab injections administered through
month 24 in patients who completed the study or discontinued
early is depicted in Figure 3. During year 1, the ranibizumab
monthly dosed groups averaged 11.3 (0.5 mg) and 11.2 (2.0 mg)
injections, whereas the ranibizumab PRN-dosed groups averaged
7.7 (0.5 mg) and 6.9 (2.0 mg) injections. During year 2, the rani-
bizumab monthly dosed groups averaged 10.1 (0.5 mg) and 10.4
(2.0 mg) injections, and the ranibizumab PRN-dosed groups
averaged 5.6 (0.5 mg) and 4.3 (2.0 mg) injections. The total mean
number of ranibizumab injections over 2 years was 21.4 and 21.6
in the ranibizumab 0.5 mg and 2.0 mg monthly groups, respec-
tively, and was 13.3 and 11.2 in the 0.5 mg PRN and 2.0 mg PRN
groups, respectively.
The treatment interval in the ranibizumab PRN groups and the
injection frequency in a subset of patients receiving ranibizumab
PRN were explored post hoc. For patients who completed the study
(n ¼ 237 for each PRN group), the median number of injections
was 14.0 in the ranibizumab 0.5 mg PRN group (Fig 4A) and was
11.0 in the 2.0 mg PRN group (Fig 4B), with patients requiring 3 to
24 injections over 2 years. For patients in the 0.5 mg PRN group
who received all 3 loading doses and completed the study (n ¼
232), the average treatment interval was 9.9 weeks after 3 monthly
loading doses; among these patients, 7% received 24 ranibizumab
injections (i.e., dosing once monthly), 44% received 14 to 23 in-
jections (i.e., dosing every >37 days but 74 days), and 49%
received 3 to 13 injections (i.e., dosing every >75 days; Fig 5A).
Mean changes in BCVA from baseline at month 24
were þ7.9, þ6.7, and þ9.7 letters for these 3 injection
categories, respectively. For patients in the 2.0 mg PRN groupPoints at Months 12 and 24
Ranibizumab Treatment Group
PRN
275)
2.0 mg Monthly
(N ¼ 274)
2.0 mg PRN
(N ¼ 273)
3.3) 9.2 (14.6) 8.6 (13.8)
4.7) 8.0 (17.4) 7.6 (15.3)
0.2) 99 (36.1) 90 (33.0)
3.1) 103 (37.6) 95 (34.8)
4.5) 256 (93.4) 259 (94.9)
0.9) 247 (90.1) 250 (91.6)
2.7) 33 (12.0) 37 (13.6)
6.2) 137 (50.0) 119 (43.6)
7.6) 134 (48.9) 122 (44.7)
1.3) 41 (15.0) 39 (14.3)
.4) 31 (11.3) 33 (12.1)
0.2) 35 (12.8) 39 (14.3)
inopathy Study; PRN ¼ pro re nata (as needed); SD ¼ standard deviation.
2185
Figure 3. Bar graph showing the mean number of ranibizumab injections
through month 24 in patients who completed the study or discontinued
early. PRN ¼ pro re nata (as needed).
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232), the average treatment interval was 12.5 weeks after 3
monthly loading doses; among these patients, 2% received 24
ranibizumab injections, 29% received 14 to 23 injections, and 69%
received 3 to 13 injections (Fig 5B). Mean changes from baseline
in BCVA at month 24 were þ12.6, þ8.5, and þ7.8 letters for these
3 injection categories, respectively.
Anatomic End Points
Spectral-Domain Optical Coherence Tomography End
Points. All groups showed a rapid reduction in CFT by SD-OCT
at day 7 that continued through month 3 and was sustained from
months 3 to 24 (Fig 6). At month 24, the mean change fromFigure 4. Bar graphs showing the distribution of the number of ranibizumab inj
and (B) the 2.0 mg PRN group in patients who completed the study. SD ¼ st
2186baseline was 182.5 mm (0.5 mg monthly), 172.0 mm (0.5 mg
PRN), e171.8 mm (2.0 mg monthly), and 181.0 mm (2.0 mg
PRN). The difference in CFT between months 12 and 24 ranged
from 9 to 11 mm.
Angiographic End Points. All 4 ranibizumab treatment
groups showed regression of total lesion area and total CNV area
from baseline over time on ﬂuorescein angiography. The mean
change from baseline in total CNV area at month 24 was 1.98
DAs (0.5 mg monthly), 1.60 DAs (0.5 mg PRN), 2.59 DAs
(2.0 mg monthly), and 1.92 DAs (2.0 mg PRN). The mean
change from baseline in total lesion area at month 24 was 1.57
DAs (0.5 mg monthly), 1.10 DAs (0.5 mg PRN), 2.12 DAs
(2.0 mg monthly), and 1.36 DAs (2.0 mg PRN).
Safety Outcomes
Ocular Adverse Events. Ocular SAEs in the study eye through
month 24 are summarized in Table 3. Ocular SAEs were mostly
singular in nature, occurring in <4% of patients across all
treatment groups. No new safety events were identiﬁed over 2
years. There were no SAEs of glaucoma and only 1 report
(0.4%) of increased intraocular pressure in the ranibizumab
0.5 mg monthly group. Endophthalmitis was reported in 4 pa-
tients (1.5%) in the 0.5 mg monthly group and 1 patient (0.4%) in
the 2.0 mg monthly group. No new reports of iridocyclitis or retinal
tear were reported in year 2 of the trial.
Ocular AEs in the study eye (including those that were SAEs)
over 2 years also were balanced among the treatment groups, with
no dose response (0.5 vs. 2.0 mg) or dose exposure (monthly vs.
PRN) trends observed. Increased intraocular pressure was reportedections over 2 years in (A) the 0.5 mg pro re nata (PRN; as needed) group
andard deviation.
Figure 5. Bar graph showing the number of ranibizumab injections over 2
years in (A) the 0.5 mg pro re nata (PRN; as needed) group and (B) the 2.0
mg PRN group among patients who received all 3 loading doses and
completed the study (n ¼ 232). BCVA ¼ best-corrected visual acuity.
Figure 6. Graph showing the mean change in central foveal thickness
(CFT) from baseline measured by spectral-domain optical coherence
tomography over time up to month 24. The last observation carried forward
method was used to impute missing data. Vertical bars are 1 standard
error of the mean. M ¼ month; PRN ¼ pro re nata (as needed).
Ho et al  HARBOR Study 2-Year Resultsin 16 patients (5.8%) in the 0.5 mg monthly group, 10 patients
(3.6%) in the 0.5 mg PRN group, 13 patients (4.7%) in the 2.0 mg
monthly group, and 10 patients (3.7%) in the 2.0 mg PRN group.
Rates of glaucoma and iritis were low, with overall rates of 1.0%
and 1.1%, respectively, among the 4 treatment groups.
Systemic Adverse Events. Systemic AEs, which were
categorized by APTC ATEs and AEs of special interest (AESI)
potentially related to systemic VEGF inhibition, were well
balanced among treatment groups, with no obvious dose-response
or dose-exposure trends observed (Table 4). Total APTC events
were low, reported in 6.6% of patients in the 0.5 mg monthly
group, 4.7% in the 0.5 mg PRN group, 5.8% in the 2.0 mg monthly
group, and 5.9% in the 2.0 mg PRN group. The overall rate of
death over 2 years was 4.7% (0.5 mg monthly), 3.6% (0.5 mgPRN), 3.6% (2.0 mg monthly), and 4.0% (2.0 mg PRN). The rates
of nonfatal myocardial infarction and overall nonfatal cerebro-
vascular accidents were low (1.8%e2.9% and 0.4%e1.1%,
respectively) and were similar among the treatment groups.
Adverse events of special interest were balanced among the 4
treatment groups, ranging from 8.8% to 10.2%, with no evident
dose-response or dose-exposure trends observed (Table 4). Rates
of central nervous systemerelated bleeding events were similar
among the 4 treatment groups: 2 patients (0.7%) in the 0.5 mg
monthly group, 4 patients (1.5%) in the 0.5 mg PRN group, 2
patients (0.7%) in the 2.0 mg monthly group, and 3 patients (1.1%)
in the 2.0 mg PRN group. Hypertension also was uncommon, re-
ported in 0 patients (0%) in the 0.5 mg monthly group, 1 patient
(0.4%) in the 0.5 mg PRN group, 1 patient (0.4%) in the 2.0 mg
monthly group, and 3 patients (1.1%) in the 2.0 mg PRN group.Discussion
The objectives for the ﬁrst year of the HARBOR study were
to assess the efﬁcacy of the ranibizumab 2.0 mg monthly
dose compared with the 0.5 mg monthly dose (superiority
comparison), to evaluate the 0.5 mg PRN and 2.0 mg PRN
dosing regimens compared with the 0.5 mg monthly dosing
regimen (2 noninferiority comparisons using a 4-letter
noninferiority margin), and to evaluate the safety of both
ranibizumab doses administered monthly and PRN.7
Although the prespeciﬁed superiority and noninferiority
comparisons were not met at year 1 of the HARBOR trial,
mean BCVA improvements were clinically meaningful
and similar in all treatment groups over 12 months. Mean
changes in BCVA from baseline at month 12 were þ10.1
letters (0.5 mg monthly), þ8.2 letters (0.5 mg PRN), þ9.2
letters (2.0 mg monthly), and þ8.6 letters (2.0 mg PRN).7
These results are similar to the visual improvements
achieved with ﬁxed ranibizumab 0.5 mg monthly dosing
at month 12 in the ANCHOR4,5 and MARINA6 trials2187
Table 3. Serious Ocular Adverse Events in the Study Eye through Month 24
Ocular SAEs in the Study Eye
Ranibizumab Treatment Group, n (%)
0.5 mg Monthly (N ¼ 274) 0.5 mg PRN (N ¼ 275) 2.0 mg Monthly (N ¼ 274) 2.0 mg PRN (N ¼ 272)
Any SAE* 7 (2.6) 7 (2.5) 10 (3.6) 4 (1.5)
Reduced visual acuity 1 (0.4) 4 (1.5) 5 (1.8) 2 (0.7)
Retinal hemorrhage 0 (0) 1 (0.4) 1 (0.4) 1 (0.4)
Endophthalmitis 4 (1.5) 0 (0) 1 (0.4) 0 (0)
Corneal edema 0 (0) 1 (0.4) 1 (0.4) 0 (0)
Iridocyclitis 0 (0) 0 (0) 1 (0.4) 0 (0)
Macular degeneration 1 (0.4) 0 (0) 0 (0) 0 (0)
Retinal artery occlusion 1 (0.4) 0 (0) 0 (0) 0 (0)
Retinal tear 0 (0) 0 (0) 1 (0.4) 0 (0)
Retinal vein occlusion 1 (0.4) 0 (0) 0 (0) 0 (0)
Vitreous ﬂoaters 0 (0) 0 (0) 1 (0.4) 0 (0)
Retinal detachment 0 (0) 0 (0) 2 (0.7) 0 (0)
Age-related macular degeneration 0 (0) 1 (0.4) 0 (0) 0 (0)
Herpes zoster ophthalmic 0 (0) 1 (0.4) 0 (0) 0 (0)
Medication error 0 (0) 0 (0) 0 (0) 1 (0.4)
Vitreous hemorrhage 0 (0) 0 (0) 0 (0) 1 (0.4)
Intraocular pressure increased 1 (0.4) 0 (0) 0 (0) 0 (0)
PRN ¼ pro re nata (as needed); SAE ¼ serious adverse event.
*Denotes total number of patients with 1 SAE. An adverse event was classiﬁed as an SAE if it caused or led to death, required prolonged hospitalization,
resulted in persistent or signiﬁcant disability, or was considered a signiﬁcant medical event by the investigating physician.
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year of HARBOR, patients in the 0.5 mg and 2.0 mg
PRN groups achieved improvements in BCVA similar to
those in the 0.5 mg and 2.0 mg monthly groups, but the
PRN groups required, on average, approximately 4 fewer
injections compared with the monthly groups (7.7 and 6.9
injections vs. 11.3 and 11.2 injections, respectively).7
In year 2 of HARBOR, the VA gains achieved in year 1
largely were maintained in both the monthly and PRN
treatment groups; similar visual gains were observed be-
tween PRN and monthly dosing, with fewer injections
required in the PRN groups over 24 months (104 weeks). At
year 2, the mean changes in BCVA from baseline wereþ9.1
(0.5 mg monthly), þ7.9 (0.5 mg PRN), þ8.0 (2.0 mg
monthly), and þ7.6 (2.0 mg PRN) letters; these VA im-
provements were achieved with a mean of 10.1, 5.6, 10.4,
and 4.3 injections in year 2, respectively. Over 24 months, a
total of 13.3 and 11.2 injections, on average, were admin-
istered in the 0.5 mg and 2.0 mg PRN groups, respectively,
compared with a total of 21.4 and 21.6 injections, on
average, in the 0.5 mg and 2.0 mg monthly groups,
respectively. From month 12 to month 24, BCVA generally
was maintained in the 0.5 mg PRN group (difference
of 0.3 letters) and decreased, on average, by 1.0 letter in
the 0.5 mg monthly and 2.0 mg PRN groups and by 1.2
letters in the 2.0 mg monthly group. These results demon-
strate that PRN therapy can maintain the vision gains
achieved in year 1 out to year 2 when patients are followed
up using visual acuity and strict SD-OCT re-treatment
criteria.
Patients receiving ranibizumab 0.5 mg and 2.0 mg PRN
had individualized responses to treatment, as evidenced
by a post hoc analysis of injection frequency in PRN-dosed
patients who completed the study (n ¼ 237 in each group).2188In the 0.5 mg PRN group, the total number of ranibizumab
injections ranged from 3 to 24 per patient over 2 years
(median, 14.0 injections; Fig 4A); for patients who received
all 3 loading doses of 0.5 mg and completed the study (n ¼
232), the average treatment interval was 9.9 weeks
following the 3 monthly loading doses, and 93% of these
patients did not require monthly dosing (Fig 5A). In the
2.0 mg PRN group, the total number of ranibizumab in-
jections ranged from 4 to 24 per patient over 2 years
(median, 11.0 injections; Fig 4B); for patients who received
all 3 loading doses of 2.0 mg and completed the study (n ¼
232), the average treatment interval was 12.5 weeks
following the 3 monthly loading doses, and 98% of these
patients did not require monthly dosing (Fig 5B).
Approximately 2 fewer injections were required, on
average, in the 2.0 mg PRN group compared with the
0.5 mg PRN group over 2 years, suggesting a slight increase
in the durability of the higher 2.0 mg dose compared with
the 0.5 mg dose, although this did not translate to an in-
crease in efﬁcacy in this study. With an estimated intra-
vitreal half-life of 9 days in humans,25 the 2.0 mg dose,
which is 4 times the marketed dose, adds 2 additional
intravitreal half-life periods compared with the 0.5 mg dose.
This increase would provide for approximately 18 days, on
average, of additional residence time in the eye, which is
consistent with the additional approximately 2.6 weeks of
average durability observed in this study. The results of the
post hoc analysis of injection frequency demonstrate that the
PRN dosing regimen results in a broad range of the number
of injections over 2 years (3e24 injections for the 0.5 mg
PRN group), which supports individualized dosing and
further suggests that patients may be overtreated or under-
treated with a ﬁxed dosing interval (e.g., injections monthly
or every 2 months, respectively).
Table 4. Key Systemic Adverse Events through Month 24
Systemic Adverse Events
Ranibizumab Treatment Group, n (%)
0.5 mg Monthly (N ¼ 274) 0.5 mg PRN (N ¼ 275) 2.0 mg Monthly (N ¼ 274) 2.0 mg PRN (N ¼ 272)
APTC ATEs
Any APTC events* 18 (6.6) 13 (4.7) 16 (5.8) 16 (5.9)
Deaths, overall 13 (4.7) 10 (3.6) 10 (3.6) 11 (4.0)
Vascular 9 (3.3) 7 (2.5) 6 (2.2) 4 (1.5)
Unknown cause 2 (0.7) 1 (0.4) 0 (0) 2 (0.7)
Nonfatal myocardial infarction 7 (2.6) 5 (1.8) 8 (2.9) 7 (2.6)
Nonfatal CVA, overall 2 (0.7) 1 (0.4) 2 (0.7) 3 (1.1)
Hemorrhagic CVA 1 (0.4) 0 (0) 0 (0) 0 (0)
Ischemic CVA 1 (0.4) 1 (0.4) 2 (0.7) 3 (1.1)
Serious AESI
Any AESIy 27 (9.9) 28 (10.2) 27 (9.9) 24 (8.8)
ATE 14 (5.1) 13 (4.7) 14 (5.1) 11 (4.0)
Bleeding/hemorrhage (CNS) 2 (0.7) 4 (1.5) 2 (0.7) 3 (1.1)
Bleeding/hemorrhage (non-CNS) 5 (1.8) 7 (2.5) 7 (2.6) 7 (2.6)
Congestive heart failure 8 (2.9) 7 (2.5) 2 (0.7) 8 (2.9)
Fistulae 0 (0) 1 (0.4) 1 (0.4) 0 (0)
Gastrointestinal perforation 0 (0) 0 (0) 1 (0.4) 0 (0)
Hypertension 0 (0) 1 (0.4) 1 (0.4) 3 (1.1)
Venous thrombotic events 1 (0.4) 1 (0.4) 2 (0.7) 1 (0.4)
Wound healing complications 0 (0) 1 (0.4) 0 (0) 0 (0)
AESI ¼ adverse event of special interest; APTC ¼ Antiplatelet Trialists’ Collaboration; ATEs ¼ arterial thromboembolic events; CNS ¼ central nervous
system; CVA ¼ cerebrovascular accident; PRN ¼ pro re nata (as needed).
*Denotes total number of patients with 1 APTC events (including vascular deaths, deaths of unknown cause, nonfatal myocardial infarctions, and
nonfatal CVAs).
yDenotes total number of patients with 1 serious AESI.
AESI classiﬁcation: adverse events related to vascular endothelial growth factor inhibition as deﬁned in Genentech, Inc. (South San Francisco, CA)
bevacizumab (Avastin) oncology trials.
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bizumab PRN groups in the HARBOR study compare
favorably with ﬁndings reported in other wet AMD trials
investigating nonmonthly dosing regimens with VEGF in-
hibitors (Fig 7). The Comparison of Age-Related Macular
Degeneration Treatments Trials (CATT) was a large, ran-
domized, noninferiority (noninferiority margin deﬁned as 5
letters) study designed to evaluate the relative efﬁcacy and
safety of ranibizumab and bevacizumab (Avastin; Gen-
entech, Inc., South San Francisco, CA) administered
monthly or PRN for 2 years (104 weeks).8,9 Patients
assigned to the PRN groups were administered 1 loading
dose of either VEGF inhibitor, followed by PRN dosing
with monthly monitoring through 2 years. Time-domain
OCT was used for approximately 77% of scans
throughout the 2-year trial (SD-OCT was used for approx-
imately 23% of scans during the second year).9 For those
CATT patients who initially were randomized to
ranibizumab 0.5 mg PRN (n ¼ 298) and remained on this
treatment regimen for the 2-year period (n ¼ 264), the
mean BCVA change at year 2 was þ6.7 letters, achieved
with a mean of 12.6 injections (5.7 injections in year 2).9
For those CATT patients who initially were randomized to
bevacizumab 1.25 mg PRN (n ¼ 300) and remained on
this treatment regimen for the 2-year period (n ¼ 251),
the mean BCVA change at year 2 was þ5.0 letters, achieved
with mean of 14.1 injections (6.4 injections in year 2;
Fig 7).9The VEGF Trap-Eye: Investigation of Efﬁcacy and
Safety in Wet AMD studies (VIEW 1 and VIEW 2) were
methodologically identical studies that compared different
dosing regimens of aﬂibercept (Eylea; Regeneron Pharma-
ceuticals, Inc., Tarrytown, NY) versus ranibizumab 0.5 mg
for 2 years (96 weeks).11 In year 1 of VIEW 1/2,
ranibizumab and aﬂibercept were administered as 3
loading doses, followed by ﬁxed dosing every 4 weeks
(q4w) (ranibizumab 0.5 mg, aﬂibercept 0.5 mg, and
aﬂibercept 2.0 mg) or every 8 weeks (q8w) (aﬂibercept
2.0 mg).11 In year 2 of VIEW 1/2, patients continued their
original dosing assignment and were switched to a capped
PRN regimen in which they were assessed monthly with
mandatory re-treatment at least every 12 weeks.11 At year
2, the ranibizumab 0.5 mg q4w/PRN group (n ¼ 595)
gained a mean of þ7.9 letters, achieved with a mean of 16.5
injections (4.7 in year 2; n ¼ 513); the aﬂibercept 2.0 mg
q4w/PRN group (n ¼ 613) gained a mean of þ7.6 letters,
achieved with a mean of 16.0 injections (4.1 in year 2; n ¼
529); the aﬂibercept 0.5 mg q4w/PRN group (n ¼ 597)
gained a mean of þ6.6 letters, achieved with a mean of 16.2
injections (4.6 in year 2; n ¼ 499); and the aﬂibercept
2.0 mg q8w/PRN group (n ¼ 607) gained a mean of þ7.6
letters, achieved with a mean of 11.2 injections (4.2 in year
2; n ¼ 511; Fig 7).26
Although there are obvious limitations to cross-trial
comparisons, less-frequently-than-monthly dosing with
ranibizumab 0.5 mg in the HARBOR, CATT, and VIEW2189
Figure 7. Bar graphs showing cross-trial comparison of the mean number of injections in year 2 with pro re nata (PRN; as needed) dosing. Numbers
below bars indicate mean changes in best-corrected visual acuity (BCVA) from baseline to month 24. Cross-trial comparisons have limitations and data
must be interpreted with caution. yIn year 1 of the pHase III, double-masked, multicenter, randomized, Active treatment-controlled study of the efﬁcacy
and safety of 0.5 mg and 2.0 mg Ranibizumab administered monthly or on an as-needed Basis (PRN) in patients with subfoveal neOvasculaR age-
related macular degeneration (HARBOR) trial, ranibizumab (RBZ) was administered as 3 loading doses, followed by PRN dosing through year 2.
zIn year 1 of Comparison of Age-related Macular Degeneration Treatments Trials (CATT), RBZ and bevacizumab (BVZ) were administered as 1
loading dose, followed by PRN dosing through year 2. #In year 1 of VEGF Trap-Eye: Investigation of Efﬁcacy and Safety in Wet AMD (VIEW) 1 and 2,
RBZ and aﬂibercept (VTE) were administered as 3 loading doses, followed by ﬁxed q4w (RBZ) or q8w (VTE) dosing; in VIEW 1/2 year 2, RBZ and
VTE were administered PRN at least every 12 weeks. q4w ¼ every 4 weeks; q8w ¼ every 8 weeks; VEGF ¼ vascular endothelial growth factor.
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VA gains over 24 months: HARBOR, þ7.9 letters at 104
weeks; CATT, þ6.7 letters at 104 weeks; VIEW 1/2, þ7.9
letters at 96 weeks (Fig 7). Additionally, during year 2,
when injections were given PRN based on prespeciﬁed re-
treatment criteria, the mean number of treatments in the
ranibizumab 0.5 mg groups was similar across all 3 trials:
HARBOR, 5.6 injections; CATT, 5.7 injections; VIEW 1/2,
4.7 injections (Fig 7).
In year 2 of the VIEW 1/2 studies, when the ranibizu-
mab 0.5 mg q4w/PRN and aﬂibercept 2.0 mg q8w/PRN
groups were dosed according to the same capped PRN
treatment schedule, mean injection frequencies were
similar between groups (4.7 and 4.2 injections, respec-
tively; Fig 7). Mean vision gain at 96 weeks also was
comparable between groups (þ7.9 and þ7.6 letters,
respectively; Fig 7).
Overall, the incidence of ocular AEs observed in the
study eye through month 24 of the HARBOR study was
comparable among treatment groups and is consistent
with previous large trials evaluating ranibizumab for wet
AMD. Ocular SAEs in the study eye reported during the
2-year trial mostly were singular in nature, occurring in
<4% of patients across treatment groups, with no new
safety events identiﬁed. Endophthalmitis was reported in
3 patients in the monthly groups during year 2 (n ¼ 2
with 0.5 mg and n ¼ 1 with 2.0 mg). The incidence of
retinal hemorrhage and iridocyclitis remained unchanged2190through the second year of the trial. An increase in
intraocular pressure was reported in 1 patient in the
0.5 mg monthly group. Other SAEs reported in the study
eye are shown in Table 3. The rates of systemic AEs also
were comparable among ranibizumab treatment groups,
indicating that there was no evident dose-response
trends (0.5 mg vs. 2.0 mg) or dose-exposure trends
(monthly vs. PRN) observed over 2 years in the
HARBOR study.
In conclusion, the HARBOR 2-year results demonstrate
that all 4 ranibizumab treatment groups maintained their
visual and anatomic improvements, on average, between
months 12 and 24 of the study. Over 2 years, the 2.0 mg
dose did not show any clinically meaningful difference in
efﬁcacy, durability, or safety compared with the 0.5 mg
ranibizumab dose. The PRN administration of ranibizu-
mab 0.5 mg and 2.0 mg was efﬁcacious, with safety pro-
ﬁles consistent with those of previous ranibizumab studies
in wet AMD, and provided durable results with less
frequent dosing. The VA gains achieved in the 0.5 mg PRN
group had the least amount of change from months 12 to
24 (0.3 letters) compared with the other ranibizumab
treatment groups. Most patients (93%) in the 0.5 mg PRN
group did not require monthly dosing over 2 years, indi-
cating that an individualized treatment approach with
ranibizumab 0.5 mg using visual acuity and SD-OCTe
guided re-treatment criteria may be appropriate for most
patients with wet AMD.
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